Status:

UNKNOWN

Thymoglobulin Induction in Kidney Transplant Recipients

Lead Sponsor:

University of Oxford

Collaborating Sponsors:

Oxford University Hospitals NHS Trust

Genzyme, a Sanofi Company

Conditions:

Kidney Transplantation

Ischemia-Reperfusion Injury

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage that kidneys transplanted...

Detailed Description

The increasing disparity between organ availability and the number of patients on waiting list for a transplant has led to different strategies to improve half life of all transplants. One such method...

Eligibility Criteria

Inclusion

  • Participant is willing and able to give informed consent for participation in the study
  • Male or Female, aged 18 years or above
  • Recipient of DCD kidney transplant
  • Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the first 12 months of the study
  • Able (in the Investigators opinion) and willing to comply with all study requirements
  • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study

Exclusion

  • The participant may not enter the study if ANY of the following apply:
  • Failure of either recipient of a pair of kidneys to give consent
  • Female participant who is pregnant, lactating or planning pregnancy during the course of the study.
  • History of specific viral infection that would contraindicate depleting antibody therapy e.g. hepatitis B\&C, HIV
  • Significant hepatic impairment-.i.e. Values 3 times upper limit of normal (unless this is usual for the subject)
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
  • Participants who have participated in another research study involving an investigational product in the previous 12 weeks
  • Previous administration of Thymoglobuline
  • Patients with functioning non-renal transplants and on immunosuppression
  • The patient is not suitable, in the opinion of the Investigator, to take part in the trial

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2016

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT01239563

Start Date

January 1 2011

End Date

May 1 2016

Last Update

November 11 2010

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Oxford Transplant Centre, Churchill Hospital

Oxford, Oxfordshire, United Kingdom, OX3 7LJ

2

University of Oxford

Oxford, Oxfordshire, United Kingdom, OX3 9DU

Thymoglobulin Induction in Kidney Transplant Recipients | DecenTrialz